Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Syndax Pharmaceuticals (SNDX) EBIAT (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has 6 years of EBIAT data on record, last reported at -$20.4 million in Q4 2020.

  • For Q4 2020, EBIAT fell 45.88% year-over-year to -$20.4 million; the TTM value through Dec 2020 reached -$73.2 million, down 30.53%, while the annual FY2025 figure was -$285.4 million, 10.46% up from the prior year.
  • EBIAT reached -$20.4 million in Q4 2020 per SNDX's latest filing, roughly flat from -$20.4 million in the prior quarter.
  • Across five years, EBIAT topped out at -$8.4 million in Q2 2016 and bottomed at -$20.4 million in Q3 2020.
  • Average EBIAT over 5 years is -$15.4 million, with a median of -$15.0 million recorded in 2016.
  • Peak YoY movement for EBIAT: crashed 110.34% in 2016, then rose 26.27% in 2019.
  • A 5-year view of EBIAT shows it stood at -$10.8 million in 2016, then crashed by 76.64% to -$19.1 million in 2017, then grew by 1.4% to -$18.8 million in 2018, then increased by 25.68% to -$14.0 million in 2019, then tumbled by 45.88% to -$20.4 million in 2020.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$20.4 million in Q4 2020, -$20.4 million in Q3 2020, and -$17.1 million in Q2 2020.